These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1126 related articles for article (PubMed ID: 25649668)

  • 1. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
    J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.
    Kwakernaak AJ; Lambert G; Dullaart RP
    Clin Biochem; 2014 May; 47(7-8):679-82. PubMed ID: 24680982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B; Duvillard L; Brindisi MC; Gautier E; Krempf M; Costet P; Cariou B
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
    Chan DC; Hamilton SJ; Rye KA; Chew GT; Jenkins AJ; Lambert G; Watts GF
    Diabetes Obes Metab; 2010 Sep; 12(9):752-6. PubMed ID: 20649626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment.
    Kwakernaak AJ; Lambert G; Slagman MC; Waanders F; Laverman GD; Petrides F; Dikkeschei BD; Navis G; Dullaart RP
    Atherosclerosis; 2013 Feb; 226(2):459-65. PubMed ID: 23261172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders.
    Ibarretxe D; Girona J; Plana N; Cabré A; Ferré R; Amigó N; Guaita S; Mallol R; Heras M; Masana L
    Clin Investig Arterioscler; 2016; 28(2):71-8. PubMed ID: 26743379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H; Bissonnette S; Saint-Pierre N; Lamantia V; Cyr Y; Chrétien M; Faraj M
    J Clin Lipidol; 2015; 9(5):664-75. PubMed ID: 26350813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.
    Zhu YM; Anderson TJ; Sikdar K; Fung M; McQueen MJ; Lonn EM; Verma S
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2254-9. PubMed ID: 26293463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2.
    Brouwers MC; van Greevenbroek MM; Konrad RJ; Troutt JS; Schaper NC; Stehouwer CD
    Clin Sci (Lond); 2014 May; 126(9):679-84. PubMed ID: 24308640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.